En

September 8-12, 1996Maastricht, The Netherlands

Major topics:
- Methodology and Design in Medicinal Chemistry
- The Genome as Target for Drug Design
- Enzymes and Enzyme-inhibitors
- CNS agents
- Antibacterial and Antifungal Drug Discovery

Organised by:
  • Société Royale de Chimie (SRC), Medicinal Chemistry Division (Belgium)
  • Section Medicinal Chemistry, Royal Netherlands Chemical Society (KNCV) (The Netherlands)

September 6-10, 1998Edinburgh, Scotland

The following themes were included in the coverage:

- New Technologies for Drug Discovery
- Ion Channels
- Intracellular Signalling
- Glycine Antagonists
- Predicting DMPK
- Growth Factors
- Glycochemistry and Glycobiology
- 7TM Receptors
- Protease Inhibition

Organised by:
  • The Biological and Medicinal Chemistry Sector (BMCS) of the Royal Society of Chemistry (RSC) (United Kingdom)

September 18-22, 2000Bologna, Italy

Main topics inlcuded:
- Antihypertensive Agents
- The Impact of Organic Chemistry on Drug Discovery
- Antiinfective Agents
- Hypolipidemics/Antiatherosclerotics
- Anticancer Agents

Organised by:
  • Division of Medicinal Chemistry of the Italian Chemical Society (Divisione di Chimica Farmaceutica - Società Chimica Italiana, DCF-SCI) (Italy)

September 1-5, 2002Barcelona, Spain

The Symposium focussed on the following topics:
- New methods and technologies in drug discovery
- Development of chemical libraries
- Early ADMET assessment
- Special topics in organic chemistry oriented to drug development

Organised by:
  • Sociedad Española de Química Terapéutica (Spain)

August 15-19, 2004Copenhagen, Denmark & Malmoe, Sweden

The XVIIIth ISMC will reflect that medicinal chemistry is a scientific discipline undergoing rapid development. The molecular biological revolution, new drug design technologies and the progressing mapping of the human genome have created a new exciting working field for scientists in these research areas. These developments are continuously broadening the borderlands between chemistry, informatics and biology and provide new opportunities for drug design on a rational basis. The ISMC 2004 will illustrate the integration of the complementary industrial and academic drug design  approaches.

Organised by:
  • The Danish Society for Medicinal Chemistry and Chemical Biology (Denmark)
  • Swedish Pharmaceutical Society (Sweden)

August 29 - September 2, 2006Istanbul, Turkey

The Symposium will focus on important new scientific and technological developments in the drug discovery process; particularly those relevant to medicinal chemistry. The meeting will create an environment for in-depth, informed discussions highlighting the importance of medicinal chemistry in the pharmaceutical industry, academia and drug research. It will also provide opportunities to re-emphasise the crucial position of medicinal chemistry in the drug discovery process and its pivotal role in linking and exploiting the associated biological sciences. Therefore, the ISMC-2006 intends to create a forum for all scientists interested in medicinal chemistry and related fields.

Organised by:
  • Turkish Association of Medicinal and Pharmaceutical Chemistry (Turkey)

August 31 - September 4, 2008Vienna, Austria

The Symposium will focus on important new scientific and technological developments in the drug discovery process; particularly those relevant to medicinal chemistry. The meeting will create an environment for in-depth, informed discussions highlighting the importance of medicinal chemistry in the pharmaceutical industry, academia and drug research. It will also provide opportunities to re-emphasise the crucial position of medicinal chemistry in the drug discovery process and its pivotal role in linking and exploiting the associated biological sciences. Therefore, ISMC-2008 intends to create a forum for all scientists interested in medicinal chemistry and related fields.

Organised by:
  • Austrian Chemical Society, Medicinal Chemistry Section (Austria)

September 5-9, 2010Brussels, Belgium

EFMC-ISMC 2010 was organised by the Medicinal Chemistry Divisions of the "Société Royale de Chimie (SRC)" and the "Koninklijke Vlaamse Chemische Vereniging (KVCV)", on behalf of the European Federation for Medicinal Chemistry.

EFMC-ISMC 2010 continued the tradition established by these biennial International Symposia and covered drug discovery advances in all major therapeutic areas, as well as the most recent advances in lead identification and optimization strategies, in drug design and development, and in prediction of activity as well as of adverse effects. An emphasis was on first time disclosures, emerging drugs and emerging technologies, including nanatechnologies and the chemical modulation of stem cells. ISMC 2010 also illustrated the impact of the omics and biomarker area on the interfaces between chemistry, informatics, biology and experimental medicine.

Organised by:
  • Medicinal and Bioorganic Chemistry Division of Royal Flemish Chemical Society (KVCV) (Belgium)
  • Société Royale de Chimie (SRC), Medicinal Chemistry Division (Belgium)

September 2-6, 2012Berlin, Germany

EFMC-ISMC 2012 in Berlin, Germany was be jointly organised by the Division of Medicinal Chemistry of the German Chemical Society (GDCh) and the Section of Pharmaceutical/Medicinal Chemistry of the German Pharmaceutical Society (DPhG). EFMC-ISMC 2012 continued the tradition of the ISMC Symposia to create an international platform where scientists from all over the world meet and exchange their view and ideas.

The scientific programme of EFMC-ISMC 2012 covered drug discovery advances in all major therapeutic areas as well as the most recent advances in lead identification and optimization strategies, drug design and profiling technologies. Particular emphasis was put on first time disclosures. EFMC-ISMC 2012 also illustrated the impact of the -omics and biomarker areas on the interfaces between chemistry, informatics, biology and experimental medicine.

Organised by:
  • Division of Medicinal Chemistry of the German Chemical Society (GDCh) (Germany)
  • German Pharmaceutical Society, Section of Pharmaceutical/Medicinal Chemistry (Germany)

August 28 - September 1, 2016Manchester, UK

The XXV EFMC International Symposium on Medicinal Chemistry (EFMC-ISMC 2018) was organised by the Section for Medicinal Chemistry of the Slovenian Pharmaceutical Society (SFD), on behalf of the European Federation for Medicinal Chemistry (EFMC).

The 2018 edition continued the tradition established by these biennial symposia of covering drug discovery advances in major therapeutic areas, including the treatment of inflammatory and autoimmune diseases, infectious diseases including fungal infections, cardiometabolic diseases, neurodegenerative diseases and oncology. EFMC-ISMC 2018 presented the most recent advances in up-to-date topics like protein degradation, STING pathway, kinetics and pharmacokinetics of drug binding and PET imaging, and will tackle some out-of-the-box areas of Medicinal Chemistry including carbohydrate-based vaccines and new chemical modalities, while Chemical Biology approaches to target identification covered the interfaces between chemistry, biology and experimental medicine. Particular emphasis was put on first time disclosures, recent highlights in medicinal chemistry, and the impact of artificial intelligence in drug discovery.

Organised by:
  • The Biological and Medicinal Chemistry Sector (BMCS) of the Royal Society of Chemistry (RSC) (United Kingdom)

September 7-11, 2014Lisbon, Portugal

EFMC-ISMC 2014 in Lisbon, Portugal was organised by the Portuguese Chemical Society (SPQ). EFMC-ISMC 2014 continued the tradition of the ISMC Symposia to create an international platform where scientists from all over the world meet and exchange their view and ideas.

The scientific programme of EFMC-ISMC 2014 covered drug discovery advances in the major therapeutic areas, including neglected diseases, CNS disorders, inflammation, metabolic disorders, and oncology. Particular emphasis will be put on first time disclosures, recent highlights in medicinal chemistry, and organic synthesis which had a strong impact on medicinal chemistry.

Organised by:
  • Division of Medicinal Chemistry of the Portuguese Chemical Society (Portugal)

September 2-6, 2018Ljubljana, Slovenia

As decided during the Council meeting in Lisbon, September 7, 2014, the Section for Medicinal Chemistry of the Slovenian Pharmaceutical Society will organise the XXV EFMC International Symposium on Medicinal Chemistry (EFMC-ISMC 2018) on behalf of the European Federation for Medicinal Chemistry (EFMC).


The 2018 edition will continue the tradition established by these biennial symposia of covering drug discovery advances in major therapeutic areas, including the treatment of inflammatory and autoimmune diseases, infectious diseases including fungal infections, cardiometabolic diseases, neurodegenerative diseases and oncology. EFMC-ISMC 2018 will present the most recent advances in up-to-date topics like protein degradation, STING pathway, kinetics and pharmacokinetics of drug binding and PET imaging, and will tackle some out-of-the-box areas of Medicinal Chemistry including carbohydrate-based vaccines and new chemical modalities, while Chemical Biology approaches to target identification will cover the interfaces between chemistry, biology and experimental medicine. Particular emphasis will be put on first time disclosures, recent highlights in medicinal chemistry, and the impact of artificial intelligence in drug discovery.

Organised by:
  • Section for Medicinal Chemistry of the Slovenian Pharmaceutical Society (Slovenia)
  • European Federation of Medecinal Chemistry (EFMC)